J&J Pauses Trial for COVID-19 Vaccine Candidate

Johnson & Johnson (J&J) has suspended dosing in a phase 3 trial of its COVID-19 vaccine candidate Ad26.COV2.S  following a reported adverse event.

J&J said that the participant’s illness will be reviewed by the trial’s independent data safety monitoring board, but didn’t provide further details, citing the need to protect the participant’s privacy.

The late-stage trial, which began last month, aims to enroll 60,000 participants across three continents to evaluate a single vaccine dose vs. placebo.